loading page

Reinforcement-based cognitive biases as vulnerability factors in alcohol addiction: From humans to animal models
  • Karolina Noworyta,
  • Agata Cieslik,
  • Rafal Rygula
Karolina Noworyta
Maj Institute of Pharmacology Polish Academy of Sciences

Corresponding Author:[email protected]

Author Profile
Agata Cieslik
Maj Institute of Pharmacology Polish Academy of Sciences
Author Profile
Rafal Rygula
Maj Institute of Pharmacology Polish Academy of Sciences
Author Profile


Alcohol use disorder (AUD) is one of the most common but still poorly treated psychiatric conditions. Developing new treatments requires a better understanding of the aetiology of symptoms and evaluation of novel therapeutic targets in preclinical studies. Recent developments in our understanding of the reinforcement-based cognitive biases (RBCBs) that contribute to the development of AUD and its treatment offer new opportunities for both clinical and preclinical research. In this review, we first briefly describe psychological and cognitive theories that implicate various aspects of reinforcement sensitivity in the development, maintenance, and recurrence of alcohol addiction. Furthermore, in separate sections, we describe studies investigating RBCBs and their neural, neurochemical, and pharmacological correlates, and we discuss possible interactions between RBCBs and trajectories of AUD. Finally, we describe how recent translational studies using state-of-the-art animal models can facilitate our understanding of the role of reinforcement sensitivity and RBCBs in various aspects of AUD.
11 Mar 2021Submitted to British Journal of Pharmacology
12 Mar 2021Submission Checks Completed
12 Mar 2021Assigned to Editor
15 Mar 2021Reviewer(s) Assigned
27 Apr 2021Review(s) Completed, Editorial Evaluation Pending
28 Apr 2021Editorial Decision: Revise Minor
04 Jun 20211st Revision Received
14 Jun 2021Submission Checks Completed
14 Jun 2021Assigned to Editor
14 Jun 2021Reviewer(s) Assigned
29 Jun 2021Review(s) Completed, Editorial Evaluation Pending
30 Jun 2021Editorial Decision: Accept
Sep 2022Published in British Journal of Pharmacology volume 179 issue 17 on pages 4265-4280. 10.1111/bph.15613